These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 13545224)

  • 1. Newer stimulant drugs.
    LEAKE CD
    Am J Nurs; 1958 Jul; 58(7):966-8. PubMed ID: 13545224
    [No Abstract]   [Full Text] [Related]  

  • 2. [Differences between prophylactic and therapeutic effects of stimulant drugs].
    von Kerékjártó M
    Arzneimittelforschung; 1966 Feb; 16(2):308-11. PubMed ID: 6013824
    [No Abstract]   [Full Text] [Related]  

  • 3. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety.
    Heal DJ; Cheetham SC; Smith SL
    Neuropharmacology; 2009 Dec; 57(7-8):608-18. PubMed ID: 19761781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The place of stimulant drugs in the therapy of stress disorder.
    O'NEILL D
    Br J Clin Pract; 1959 May; 13(5):352-8. PubMed ID: 13651533
    [No Abstract]   [Full Text] [Related]  

  • 6. Treating problem children with stimulant drugs.
    Sroufe LA; Stewart MA
    N Engl J Med; 1973 Aug; 289(8):407-13. PubMed ID: 4146358
    [No Abstract]   [Full Text] [Related]  

  • 7. [Apropos the National Board and Welfare's report on ADDH: some views on the treatment with central nervous system stimulants].
    Zetterström R
    Lakartidningen; 2002 Aug; 99(35):3435-6. PubMed ID: 12362770
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescription stimulant expectancies in recreational and medical users: results from a preliminary expectancy questionnaire.
    Looby A; Earleywine M
    Subst Use Misuse; 2009; 44(11):1578-91. PubMed ID: 19938932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation.
    Carlson PJ; Merlock MC; Suppes T
    Bipolar Disord; 2004 Oct; 6(5):416-20. PubMed ID: 15383134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate for the treatment of Parkinson disease and other neurological disorders.
    Auriel E; Hausdorff JM; Giladi N
    Clin Neuropharmacol; 2009; 32(2):75-81. PubMed ID: 18978488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of stimulant drugs in learning and behavior disorders.
    Conners CK
    Psychopharmacol Bull; 1971 Jul; 7(3):39-40. PubMed ID: 5117857
    [No Abstract]   [Full Text] [Related]  

  • 13. Amphetamine Use in the Elderly: A Systematic Review of the Literature.
    Sassi KLM; Rocha NP; Colpo GD; John V; Teixeira AL
    Curr Neuropharmacol; 2020; 18(2):126-135. PubMed ID: 31660835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mood-altering drugs.
    Turner EJ; Arnold LE
    Pediatrics; 1971 Sep; 48(3):496-7. PubMed ID: 5094361
    [No Abstract]   [Full Text] [Related]  

  • 15. Stimulant dosing for children with ADHD: a medical claims analysis.
    Olfson M; Marcus S; Wan G
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):51-9. PubMed ID: 19218896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans.
    Stoops WW; Lile JA; Glaser PE; Rush CR
    Exp Clin Psychopharmacol; 2005 Feb; 13(1):56-64. PubMed ID: 15727504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of dextro-amphetamine and racemic-amphetamine in the treatment of the hyperkinetic syndrome or minimal brain dysfunction.
    Gross MD
    Dis Nerv Syst; 1976 Jan; 37(1):14-6. PubMed ID: 1106966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine, psychomotor stimulants, and schizophrenia: effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics.
    Janowsky DS; Davis JM
    Adv Biochem Psychopharmacol; 1974; 12(0):317-23. PubMed ID: 4608582
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of haloperidol on the central nervous system].
    Vinogradov VV; Krylov SS; Snegirev EA; Sysoeva AF; Khasabova VA
    Farmakol Toksikol; 1967; 30(2):131-4. PubMed ID: 4971063
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL; Kuchibhatla A
    Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.